The girl's death was never publicly reported. The research team published a paper in Nature in February 2025 claiming successful gene editing in a clinical trial, without disclosing the patient's death . The paper described preclinical work for a gene-editing treatment for Snijders Blok-Campeau syndrome but omitted any mention of the fatal outcome
. Nature has since added an editor's note to the paper and launched its own investigation, though the notice is explicitly not a retraction
.
The girl's parents raised approximately $860,000 to fund the treatment . According to the investigation, the family paid for the therapy's development and clinical administration, and were reportedly not fully informed of the risks involved
.
As of the latest reports, all three investigations are open and unresolved. No formal finding of misconduct has been announced .
The case has drawn immediate comparisons to the 2018 He Jiankui gene-edited babies scandal and has raised serious questions about regulatory oversight, informed consent, and ethical accountability in China's biomedical research sector . The investigation has also highlighted the intense global race to turn base editors — a more precise form of the CRISPR gene-editing tool — into clinical therapies for rare diseases, and the risks that can arise when scientific ambition outpaces ethical safeguards
.